trending Market Intelligence /marketintelligence/en/news-insights/trending/svX54AvZ60H7cxVdQbrd2Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Opexa Therapeutics completes merger with Acer Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Opexa Therapeutics completes merger with Acer Therapeutics

Opexa Therapeutics Inc. completed its merger with private pharma company Acer Therapeutics Inc.

Acer Therapeutics shareholders now own 88.8% of the combined company's outstanding common stock, with the remaining 11.2% owned by Opexa shareholders.

The combined company, renamed Acer Therapeutics Inc., will start trading Sept. 21 on the Nasdaq Capital Market under the symbol ACER.

Additionally, an investor group led by TVM Capital Life Sciences invested about $15.7 million in Acer Therapeutics before the deal closed.